Results 161 to 170 of about 29,030 (239)

Disproportionality analysis of drug-associated progressive multifocal leukoencephalopathy: roles of underlying diseases and immunomodulatory therapies in FAERS. [PDF]

Front Immunol
Lin X, Qin N, He B, Chen J, Zhang Y, Wang H, Liu W.   +6 more
europepmc   +1 more source

Comparative Efficacy of Ublitixumab Versus Natalizumab in the Treatment of Relapsing and Remitting Multiple Sclerosis. [PDF]

Cureus
Chitturi SV, Amith Priyansu J, Sadhu A, Ramisetty H, Pallapothu MR, Kogantii D.   +5 more
europepmc   +1 more source

Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosis. [PDF]

J Neurol Neurosurg Psychiatry
Gelissen LMY, Toorop AA, Schipper PM, Hoitsma E, Zeinstra EMPE, van Rooij LC, van Munster CEP, Vennegoor A, Mostert J, Wokke B, Kalkers NF, Hoogervorst ELJ, van Eijk J, Roosendaal CM, Kragt JJ, Eurelings M, van Genugten J, Nielsen J, Sinnige LGF, Kloosterziel ME, Arnoldus EPJ, Bouvy WH, Strijbis EM, Oosten BV, De Jong BA, Uitdehaag BMJ, Lissenberg-Witte BI, Loeff FC, Rispens T, Killestein J, van Kempen ZLE.   +30 more
europepmc   +1 more source

Comparative evaluation of STRATIFY JCV™ and IMMUNOWELL™ assays for anti-JCV antibody detection in natalizumab-treated RRMS patients. [PDF]

Ther Adv Neurol Disord
Chisari CG, Spampinato G, Crimì P, Ferraro E, Lo Fermo S, Cimino V, Zappia M, Patti F.   +7 more
europepmc   +1 more source

Access, satisfaction, adherence and safety to subcutaneous natalizumab compared to intravenous natalizumab in multiple sclerosis in a real-life cohort: first report from Latin America. [PDF]

Ther Adv Neurol Disord
Silva BA, Santajuliana F, Casas M, Lázaro L, Pita C, Cohen L, Rinaldi G, Alonso R, Míguez J, D'Alessandro S.   +9 more
europepmc   +1 more source

Patient Preference and Time Allocation Associated with Transition from Intravenous to Subcutaneous Administration of Natalizumab (Tysabri) in Patients with Relapsing Remitting MS - A Questionnaire Study. [PDF]

Patient Prefer Adherence
Almroth A, Söderbärg K, Sjöblom I.
europepmc   +1 more source

Profiling the Cerebrospinal Fluid Proteome in Progressive Multiple Sclerosis: Treatment Effects and Associations with IgM Oligoclonal Bands. [PDF]

J Neuroimmune Pharmacol
El Mahdaoui S, Kosa P, Komori M, Veiga González JL, Chow HH, Ratzer R, Madsen CG, Siebner HR, Bielekova B, Villar LM, Romme Christensen J, Sellebjerg F.   +11 more
europepmc   +1 more source

LPX-TI641, a Tim3/4 Agonist, Induces Long-Term Immune Tolerance in Multiple Sclerosis Models. [PDF]

Pharmaceutics
Fathallah AM, Ramadan A, Karzoun B, Leahy H, Dave N, Khashan R, Allababidi S, Saidha S, Madani S.   +8 more
europepmc   +1 more source

<i>ITGA4</i> genetic variants as a predictor of therapeutic responsivity to autoimmune diseases. [PDF]

Front Pharmacol
De Matos MD, Guimenes BD, Pavani GK, Fernandes GG, Montes GC, Fontes-Dantas FL.   +5 more
europepmc   +1 more source

Cost-Consequence Analysis of Natalizumab Compared with Other High-Efficacy Treatments in Patients with Relapsing-Remitting Multiple Sclerosis. [PDF]

Pharmacoeconomics
Prosperini L, Brescia Morra VB, Fornari C, Santoni L, Perini D, Bergamaschi R, Cortesi PA.   +6 more
europepmc   +1 more source